Dysfunctional Activated Protein C (PC Cádiz) in a Patient with Thrombotic Disease

Summary

The partial characterization of a dysfunctional protein C (PC), provisionally named “PC Cádiz”, in a 45-year-old male patient suffering from recurrent venous thrombosis is described. The only defect found in laboratory assays for haemostasis and hepatic function was a half normal level of both amidolytic and anticoagulant protein C activity, measured by different functional assays that use thrombin-thrombomodulin complex and a snake venom to activate protein C. Protein C antigen was always found to be within normal levels. Two young daughters of the propositus were found to have the same defect. Double-crossed immunoelectrophoresis, performed in the presence and absence of Ca²⁺ in the first dimension, showed no clear differences between patient and control PC. PC adsorption to barium salts was also found to be normal. Measurement of the PC activation peptide in the barium citrate eluates after PC activation showed no significant differences between patient and 10 normal controls, the concentration of this peptide being very similar to that of PC zymogen in the same eluates before PC activation. These results indicate that this abnormal PC is able to be normally activated by thrombin-thrombomodulin complex but does not exhibit serine protease activity, probably due to a defect in the PC molecule near the active site center.

Keywords

Dysfunctional protein C - PC activation peptide - Venous thrombosis

• References

• 1 Esmon CT. Protein C: Biochemistry, physiology and clinical implications. Blood 1983; 62: 1155-1158
• 2 Marlar RA. Protein C in thromboembolic disease. Sem Thromb Hemostas 1985; 11: 387-393
• 3 Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. New Engl J Med 1986; 314: 1298-1304
• 4 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalysed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-2252
• 5 Kisiel W. Human plasma protein C: isolation, characterization and mechanism of activation by α-thrombin. J Clin Invest 1979; 64: 761-769
• 6 Suzuki K, Stenflo J, Dahlbåck B, Teodorson B. Inactivation of human blood coagulation factor V by activated protein C. J Biol Chem 1983; 258: 1914-1920
• 7 Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63: 486-489
• 8 Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68: 1221-1228
• 9 Taylor FB, Carroll RC, Gerrard J, Esmon CT, Radcliffe RD. Lysis of clots prepared from whole blood and plasma. Fed. Proc. 1981; 40: 2092-2098
• 10 van Hinsbergh V WM, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
• 11 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82: 1121-1125
• 12 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 266: 11128-11131
• 13 DAngelo A, Lockhart MS, Viganò-DAngelo S, Taylor FB. Protein S is a cofactor for activated protein C neutralization of an inhibitor of plasminogen activation (PAI) released from platelets. Blood. 1986 (in press)
• 14 Griffin JH, Evatt B, Zimmerman TS, Kleiss A, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
• 15 Bertina RM, Broekmans AW, Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 1-5
• 16 Sala N, Owen WG, Collen D. A functional assay of protein C in human plasma. Blood 1984; 63: 671-675
• 17 Francis Jr R B, Patch MJ. A functional assay for protein C in human plasma. Thromb Res 1983; 32: 605-613
• 18 Bertina RM, Broekmans AW, Krommenhoek-van EsC, van Wijngaarden A. The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemostas 1984; 51: 1-5
• 19 Comp PC, Nixon RR, Esmon CT. Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex. Blood 1984; 63: 15-21
• 20 Vigano dAngelo S, Comp PC, Esmon CT, dAngelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77: 416-425
• 21 Barbui T, Finazzi G, Mussoni L, Riganti M, Donati MB, Colucci M, Collen D. Hereditary dysfunctional protein C (Protein C Bergamo) and thrombosis. The Lancet 1984; oct 6: 819
• 22 Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of protein C activation in humans. J Clin Invest 1984; 74: 2033-2041
• 23 Caen J, Larrieu MJ, Samama M. L’Hémostase. Méthodes d’exploration et diagnostic practique. (2nd. edition) Expansion Scientifique Française; Paris: 1975
• 24 Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin, and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-145
• 25 D’Angelo A, Viganò-D’Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S: protein S activity during oral anticoagulation, in liver disease and in disseminated intravascular coagulation. Submitted to J Clin Invest. 1986